No Data
JiangSu WuZhong Pharmaceutical Development (600200.SH): The injection of hydrochloride beta-phenylethylamine and injection of peramivir are expected to win the national pharmaceutical centralized procurement.
JiangSu WuZhong Pharmaceutical Development (600200.SH) announced that on December 12, 2024, the company under JiangSu WuZhong will...
JiangSu WuZhong Pharmaceutical Development (600200.SH): The affiliated company participated in the national Pharmaceutical centralized procurement and plans to win the bid.
On December 13th, Gelonghui reported that JiangSu WuZhong Pharmaceutical Development (600200.SH) announced that its Suzhou Pharmaceutical Factory (referred to as "Suzhou Pharmaceutical Factory") participated in the bidding work organized by the National Pharmaceutical Joint Procurement Office for national centralized pharmaceutical procurement. Suzhou Pharmaceutical Factory has passed the consistency evaluation of quality and efficacy for its generic drugs by the National Medical Products Administration, with its products, Dopamine Hydrochloride Injection and Peramivir Injection, expected to win the bid in this centralized procurement.
Recent 5.1% Pullback Isn't Enough to Hurt Long-term JiangSu WuZhong Pharmaceutical Development (SHSE:600200) Shareholders, They're Still up 100% Over 5 Years
Huachuang Securities: The retail and social services sectors are experiencing a rebound in customer traffic, with both fundamentals and valuation recovering.
Looking ahead to 2025, the service consumer sector is experiencing a rapid turnaround and repair, with both the 'broad and profound' fundamentals and valuation repair taking effect, establishing a clear trend.
Minsheng Securities: In 24Q3, the commercial retail industry in the consumer sector was affected by demand-side pressure, leading to a slowdown in revenue and profit growth across multiple sectors.
The total retail sales of 24 companies in Q1-Q3 reached 35.36 trillion yuan, with a year-on-year growth of +3.35%. The total retail sales of a single company in Q3 reached 11.76 trillion yuan, with a year-on-year growth of +2.69%, showing a slower growth rate compared to the previous quarter.
Pinning Down JiangSu WuZhong Pharmaceutical Development Co., Ltd.'s (SHSE:600200) P/S Is Difficult Right Now
Investors Aren't Buying JiangSu WuZhong Pharmaceutical Development Co., Ltd.'s (SHSE:600200) Revenues
